journal
MENU ▼
Read by QxMD icon Read
search

Hepatic Medicine: Evidence and Research

journal
https://read.qxmd.com/read/30666172/spontaneous-bacterial-peritonitis-in-patients-with-cirrhosis-incidence-outcomes-and-treatment-strategies
#1
REVIEW
Sebastián Marciano, Juan Manuel Díaz, Melisa Dirchwolf, Adrián Gadano
Spontaneous bacterial peritonitis is the most frequent bacterial infection in patients with cirrhosis. The reported incidence varies between 7% and 30% in hospitalized patients with cirrhosis and ascites, representing one of their main complications. Outcomes in patients with spontaneous bacterial peritonitis are poor since acute kidney injury, acute-on-chronic liver failure, and death occur in as much as 54%, 60%, and 40% of the patients, respectively, at midterm. Early antibiotic treatment of spontaneous bacterial peritonitis is crucial...
2019: Hepatic Medicine: Evidence and Research
https://read.qxmd.com/read/30613166/practical-steps-to-improve-chronic-hepatitis-c-treatment-in-people-with-opioid-use-disorder
#2
Carlos Roncero, Pablo Ryan, Richard Littlewood, Juan Macías, Juan Ruiz, Pedro Seijo, Raúl Felipe Palma-Álvarez, Pablo Vega
Objectives: People with a history of injecting drugs have high prevalence of hepatitis C virus (HCV) infection, and many have opioid use disorder (OUD). Modern HCV therapies with improved efficacy and tolerability are available, but access is often limited for this group, who may be underserved for health care and face social inequity. This work develops practical steps to improve HCV care in this population. Methods: Practical steps to improve HCV care in OUD populations were developed based on clinical experience from Spain, structured assessment of published evidence...
2019: Hepatic Medicine: Evidence and Research
https://read.qxmd.com/read/30532603/comparison-of-extracorporeal-cellular-therapy-elad-%C3%A2-vs-standard-of-care-in-a-randomized-controlled-clinical-trial-in-treating-chinese-subjects-with-acute-on-chronic-liver-failure
#3
Zhongping Duan, Shaojie Xin, Jing Zhang, Shaoli You, Yu Chen, Hongling Liu, Sujun Zheng, Zheng Li, Robert Ashley, Michael Millis
Background: Preliminary evidence of safety and efficacy of an extracorporeal cellular therapy (ELAD® ) has been demonstrated in subjects with acute forms of liver failure. This study compared ELAD with standard of care in Chinese subjects with acute-on-chronic liver failure (ACLF), predominantly secondary to chronic viral hepatitis. Subjects and methods: Subjects meeting eligibility criteria were randomized to either the ELAD group or the control group. All subjects received plasma exchange and venovenous hemofiltration and either ELAD treatment for 3-5 days, unless terminated early, along with standard of care or standard of care alone (control) and were then followed up for 12 weeks...
2018: Hepatic Medicine: Evidence and Research
https://read.qxmd.com/read/30498378/universal-index-for-cirrhosis-uic-index-the-development-and-validation-of-a-novel-index-to-predict-advanced-liver-disease
#4
Zohair Ahmed, Jinma Ren, Adam Gonzalez, Umair Ahmed, Saqib Walayat, Daniel K Martin, Harsha Moole, Sherri Yong, Sean Koppe, Sonu Dhillon
Aim: The purpose of this study was to create and validate a novel serological diagnostic index to predict cirrhosis of all etiologies. Methods: This was a retrospective observational study of 771 patients, age >18 years, who underwent a liver biopsy. The stage of fibrosis and routine laboratory values were recorded. The data were randomly separated into 2 datasets (training 50% and testing 50%). A stepwise logistic regression model was used to develop the novel index...
2018: Hepatic Medicine: Evidence and Research
https://read.qxmd.com/read/30319294/expert-opinion-on-the-management-of-hepatitis-c-infection-in-kuwait
#5
EDITORIAL
Motaz Fathy Saad, Saleh Alenezi, Haifaa Asker
Chronic hepatitis C virus (HCV) infection is a leading cause of death, especially in immunocompromised patients. The lack of clear prevalence data in the Middle East makes it difficult to estimate the true morbidity and mortality burden of HCV. In Kuwait, estimating the burden of disease is complicated by the constant flow of expatriates, many of whom are from HCV-endemic areas. The development of new and revolutionary treatments for HCV necessitates the standardization of clinical practice across all healthcare institutions...
2018: Hepatic Medicine: Evidence and Research
https://read.qxmd.com/read/30254497/acute-pediatric-hyperammonemia-current-diagnosis-and-management-strategies
#6
REVIEW
Nadia Savy, David Brossier, Catherine Brunel-Guitton, Laurence Ducharme-Crevier, Geneviève Du Pont-Thibodeau, Philippe Jouvet
Acute hyperammonemia may induce a neurologic impairment leading to an acute life-threatening condition. Coma duration, ammonia peak level, and hyperammonemia duration are the main risk factors of hyperammonemia-related neurologic deficits and death. In children, hyperammonemia is mainly caused by severe liver failure and inborn errors of metabolism. In an acute setting, obtaining reliable plasma ammonia levels can be challenging because of the preanalytical difficulties that need to be addressed carefully. The management of hyperammonemia includes 1) identification of precipitating factors and cerebral edema presence, 2) a decrease in ammonia production by reducing protein intake and reversing catabolism, and 3) ammonia removal with pharmacologic treatment and, in the most severe cases, with extracorporeal therapies...
2018: Hepatic Medicine: Evidence and Research
https://read.qxmd.com/read/30237746/progressive-familial-intrahepatic-cholestasis-diagnosis-management-and-treatment
#7
REVIEW
Mithat Gunaydin, Asudan Tugce Bozkurter Cil
Progressive familial intrahepatic cholestasis (PFIC) is a group of autosomal recessive cholestatic liver diseases which are subgrouped according to the genetic defect, clinical presentation, laboratory findings and liver histology. Progressive liver fibrosis, cirrhosis, and end stage liver disease (ESLD) may eventually develop. PFIC was first described in Amish descendants of Jacob Byler, therefore it was originally called Byler disease. But it can be seen anywhere on the globe. This review summarizes the main features of the subtypes of the disease and discusses the current available diagnosis, conservative and surgical therapeutic options...
2018: Hepatic Medicine: Evidence and Research
https://read.qxmd.com/read/30214326/copeptin-as-a-novel-marker-predicting-prognosis-of-liver-cirrhosis-and-its-major-complications
#8
Ahmed Khaled Tawfik, Amal Helmy, Mohamed Yousef, Sabry Abou-Saif, Abdelrahman Kobtan, Eman Asaad, Sherief Abd-Elsalam
Objectives: The aim of the work was to assess the level of copeptin as a surrogate marker predicting the severity of liver diseases and its major complications. Patients and methods: This was a cross-sectional study that included 40 patients and 10 controls and was performed in Tanta University Hospital between June 2016 and November 2016. The studied cases were divided into five groups: group I (10 patients): compensated cirrhosis; group II (10 patients): cirrhosis with gastrointestinal hemorrhage due to portal hypertension; group III (10 patients): cirrhosis with hepatorenal syndrome; group IV (10 patients): cirrhosis with liver cell failure; and group V (10 controls): normal healthy individuals...
2018: Hepatic Medicine: Evidence and Research
https://read.qxmd.com/read/30214325/hepatitis-c-in-lebanon-the-burden-of-the-disease-and-the-value-of-comprehensive-screening-and-treatment
#9
Antoine Abou Rached, Selim Abou Kheir, Jowana Saba, Salwa Assaf, Georges Kassis, Yuri Sanchez Gonzalez, Olivier Ethgen
Purpose: To analyze the hepatitis C virus (HCV) burden in Lebanon and the value of comprehensive screening and treatment for different age groups and fibrosis stages. Methods: We used a multicohort, health-state-transition model to project the number of HCV genotype 1 and 4 patients achieving a sustained virologic response 12 weeks after treatment or progressing to compensated cirrhosis (CC), decompensated cirrhosis (DCC), hepatocellular carcinoma (HCC), or liver-related death (LrD) from 2016 to 2036...
2018: Hepatic Medicine: Evidence and Research
https://read.qxmd.com/read/30013405/management-of-refractory-cirrhotic-ascites-challenges-and-solutions
#10
REVIEW
Hiroshi Fukui, Hideto Kawaratani, Kosuke Kaji, Hiroaki Takaya, Hitoshi Yoshiji
Among the various risky complications of liver cirrhosis, refractory ascites is associated with poor survival of cirrhotics and persistently worsens their quality of life (QOL). Major clinical guidelines worldwide define refractory ascites as ascites that cannot be managed by medical therapy either because of a lack of response to maximum doses of diuretics or because patients develop complications related to diuretic therapy that preclude the use of an effective dose of diuretics. Due to the difficulty in receiving a liver transplantation (LT), the ultimate solution for refractory ascites, most cirrhotic patients have selected the palliative therapy such as repeated serial paracentesis, transjugular intrahepatic portosystemic shunt, or peritoneovenous shunt to improve their QOL...
2018: Hepatic Medicine: Evidence and Research
https://read.qxmd.com/read/29950909/biomarkers-for-primary-biliary-cholangitis-current-perspectives
#11
REVIEW
Elias Kouroumalis, Demetrius Samonakis, Argyro Voumvouraki
Primary biliary cholangitis (PBC) is a chronic progressive cholestatic disease characterized by destruction of small- and medium-sized intrahepatic bile ducts. It is no longer a rare disease, since many new asymptomatic cases are incidentally identified. Liver biopsy is diagnostically critical but not always feasible or practical to be performed. Many potential, noninvasive, markers have been proposed to replace liver biopsy and further provide the assessment of disease severity and ultimate prognosis. In this review, we evaluated serum biomarkers proposed for diagnosis, extent of fibrosis, disease prognosis and attempts for early prediction of treatment response...
2018: Hepatic Medicine: Evidence and Research
https://read.qxmd.com/read/29765256/grazoprevir-elbasvir-for-the-treatment-of-adults-with-chronic-hepatitis-c-a-short-review-on-the-clinical-evidence-and-place-in-therapy
#12
REVIEW
Nimisha Sulejmani, Syed-Mohammed Jafri
Chronic hepatitis C virus (HCV) infection impacts approximately 71 million people and approximately 400,000 deaths are attributed to HCV-related liver disease annually worldwide. Mainstay of treatment for over 25 years has been pegylated interferon until the advent of protease inhibitors, which has led to all-oral HCV treatment regimens that have changed the outlook of hepatitis C treatment. Grazoprevir/elbasvir provides high rates of efficacy and tolerability and is an all-oral once daily treatment option for HCV infection...
2018: Hepatic Medicine: Evidence and Research
https://read.qxmd.com/read/29740221/effect-of-sitagliptin-on-hepatic-histological-activity-and-fibrosis-of-nonalcoholic-steatohepatitis-patients-a-1-year-randomized-control-trial
#13
Shahinul Alam, Jhumur Ghosh, Golam Mustafa, Mohammad Kamal, Nooruddin Ahmad
Background/purpose: Dipeptidyl peptidase 4 (DPP-4) expression is directly associated with hepatic lipogenesis and liver injury in nonalcoholic steatohepatitis (NASH). This study has been designed to elucidate the histological improvement of NASH with the DPP-4 inhibitor sitagliptin. Materials and methods: In this open-label randomized control trial, paired liver biopsy was taken from 40 NASH patients. Sitagliptin 100 mg was given once daily to the SL group and no sitagliptin was given to the L group for 1 year...
2018: Hepatic Medicine: Evidence and Research
https://read.qxmd.com/read/29662329/diagnosis-and-staging-of-fibrosis-in-patients-with-chronic-hepatitis-c-comparison-and-critical-overview-of-current-strategies
#14
REVIEW
Leandro César Mendes, Raquel Sb Stucchi, Aline G Vigani
In the past years, what has always been considered undisputed true in liver fibrosis staging has been challenged. Diagnostic performance of histological evaluation has proven to be significantly influenced by sample- and observer-related variabilities. Differentiation between lower levels of fibrosis remains difficult for many, if not all, test modalities, including liver biopsy but, perhaps, such a distinction is not indispensable in light of current therapeutic approaches. Biomarkers and elastography offer, nonetheless, high predictive values for advanced fibrosis and cirrhosis and correlate well with liver-related outcomes...
2018: Hepatic Medicine: Evidence and Research
https://read.qxmd.com/read/29606895/hepatic-encephalopathy-current-challenges-and-future-prospects
#15
REVIEW
Mirashini Swaminathan, Mark Alexander Ellul, Timothy Js Cross
Hepatic encephalopathy (HE) is a common complication of liver dysfunction, including acute liver failure and liver cirrhosis. HE presents as a spectrum of neuropsychiatric symptoms ranging from subtle fluctuating cognitive impairment to coma. It is a significant contributor of morbidity in patients with liver disease. HE is observed in acute liver failure, liver bypass procedures, for example, shunt surgry and transjugular intrahepatic portosystemic shunt, and cirrhosis. These are classified as Type A, B and C HE, respectively...
2018: Hepatic Medicine: Evidence and Research
https://read.qxmd.com/read/29296102/efficacy-and-safety-of-sofosbuvir-based-therapies-in-patients-with-advanced-liver-disease-in-a-real-life-cohort
#16
Blaise K Kutala, Feryel Mouri, Corinne Castelnau, Valerie Bouton, Nathalie Giuily, Nathalie Boyer, Tarik Asselah, Patrick Marcellin
Background: The combination of sofosbuvir (SOF) with ribavirin (RBV) or daclatasvir (DCV) or simeprevir (SIM) for the treatment of patients infected by chronic hepatitis C (CHC) have led to significantly increased rates of sustained virological response (SVR). However, there is only limited data regarding factors associated with treatment failure in a "real-life" cohort. Patients and methods: Consecutive treatment-naive and treatment-experienced patients F3-F4 were treated with SOF-based interferon-free therapy in our hospital from November 2013 to July 2015...
2017: Hepatic Medicine: Evidence and Research
https://read.qxmd.com/read/29158695/pnpla3-expression-and-its-impact-on-the-liver-current-perspectives
#17
REVIEW
Francesca Virginia Bruschi, Matteo Tardelli, Thierry Claudel, Michael Trauner
A single-nucleotide polymorphism occurring in the sequence of the human patatin-like phospholipase domain-containing 3 gene ( PNPLA3 ), known as I148M variant, is one of the best characterized and deeply investigated variants in several clinical scenarios, because of its tight correlation with increased risk for developing hepatic steatosis and more aggressive part of the disease spectrum, such as nonalcoholic steatohepatitis, advanced fibrosis and cirrhosis. Further, the I148M variant is positively associated with alcoholic liver diseases, chronic hepatitis C-related cirrhosis and hepatocellular carcinoma...
2017: Hepatic Medicine: Evidence and Research
https://read.qxmd.com/read/29062242/impact-of-hepatitis-c-virus-genotype-4-eradication-following-direct-acting-antivirals-on-liver-stiffness-measurement
#18
Mohammed Tag-Adeen, Ahlam Mohamed Sabra, Yuko Akazawa, Ken Ohnita, Kazuhiko Nakao
BACKGROUND: Liver fibrosis is the most important prognostic factor in chronic hepatitis C virus (HCV) patients, and Egypt shows the highest worldwide HCV prevalence with genotype-4 pre-dominance. The aim of this study was to investigate the degree of liver stiffness measurement (LSM) improvement after successful HCV eradication. PATIENTS AND METHODS: The study included 84 chronic HCV Egyptian patients, and was conducted at Qena University Hospital from November 1, 2015 till October 31, 2016...
2017: Hepatic Medicine: Evidence and Research
https://read.qxmd.com/read/29026340/economic-impact-of-the-use-of-rifaximin-550-mg-twice-daily-for-the-treatment-of-overt-hepatic-encephalopathy-in-italy
#19
Daniela Paola Roggeri, Alessandro Roggeri
PURPOSE: Hepatic encephalopathy (HE) is associated with a reduced survival, an increased risk of hospitalization for recurrences, and a reduced health-related quality of life. The purpose of the present economic analysis was to evaluate the impact on the Italian National Health Service (INHS) expenditure of the treatment with rifaximin 550 mg twice daily (Tixteller® /Tixtar® ) for the reduction of the recurrences of overt HE, with respect to the current treatment approach. PATIENTS AND METHODS: Costs associated with patients treated with rifaximin 550 mg twice daily were estimated considering the reduction in hospitalizations for HE recurrences revealed by registrative clinical trial (-50%) applied to the hospitalization rate (42...
2017: Hepatic Medicine: Evidence and Research
https://read.qxmd.com/read/28794662/erratum-hepatitis-c-infection-in-egypt-prevalence-impact-and-management-strategies-corrigendum
#20
(no author information available yet)
[This corrects the article on p. 17 in vol. 9, PMID: 28553150.].
2017: Hepatic Medicine: Evidence and Research
journal
journal
47253
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"